Biotechnology

ZyVersa Therapeutics

ZyVersa Therapeutics released FY2025 Q3 earnings on November 19, 2025 (EST), with actual revenue of USD 0 and EPS of USD -2.5586 (forecast EPS USD -0.25)

ZyVersa Therapeutics released FY2025 9 Months Earnings on November 19, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.7443

Zyversa Therapeutics Conducts Phase 2a Study on Efficacy of 2-HPβCD in Treating Type 2 Diabetic Kidney Disease

ZyVersa Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.46 (forecast EPS USD -0.4)

ZyVersa Therapeutics released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -1.1268

Zyversa Signs Warrant Exercise Incentive Agreement and Issues New Warrants

ZyVersa Receives FDA Authorization for Emergency Use of VAR 200 for Rare Kidney Disease

ZyVersa Therapeutics signs agreement to receive $10 million for clinical development

ZyVersa Reports 2025 Q1 Earnings and Seeks Additional Financing

ZyVersa Highlights Inflammatory Research or Set to Initiate Proof-of-Concept Study

ZyVersa Therapeutics released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0, actual EPS USD -0.7264 (forecast EPS USD -0.4)

Zyversa Reveals New Obesity Therapy

Michael J. Fox Foundation Supports ZyVersa's Inflammasome Research

ZyVersa Therapeutics CEO Introduces IC 100 Development Progress

ZyVersa Therapeutics CEO Supports Parasol Group's Proposal to Use Proteinuria Reduction as a Surrogate Endpoint for FSGS Drug Approval

ZyVersa Therapeutics Submits Prospectus to Sell 4.21 Million Shares

ZyVersa Therapeutics released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.7139 USD (forecast -2.73 USD)

ZyVersa Therapeutics released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -8.4803 USD (forecast -12.43 USD)

ZyVersa Therapeutics Emphasizes the Potential of IC 100 in Treating Obesity-Related Cardiomyopathy

ZyVersa Therapeutics released FY2024 Cumulative 3Q Earnings on November 14, 2024 (EST), with Revenue at 0 and EPS at -10.2726

Intelligent Bio Solutions

Anghami

UTime

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

FG MERGER II CORP COM USD0.0001 11/02/2030 (SUBS/RTS)

ESH Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

ZyVersa Therapeutics(ZVSA.US)